相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm
Quentin Lecocq et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
Jessica Bridoux et al.
BIOMOLECULES (2020)
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma
Joji Nagasaki et al.
BLOOD ADVANCES (2020)
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane et al.
BLOOD ADVANCES (2020)
Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
Yan Xing et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages
Catarina Xavier et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Renee Clift et al.
CANCER RESEARCH (2019)
Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
Xiaojie Yu et al.
MABS (2019)
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
Elena Burova et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
Quentin Lecocq et al.
BIOMOLECULES (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
Yang Du et al.
EUROPEAN RADIOLOGY (2019)
Theranostics in immuno-oncology using nanobody derivatives
Quentin Lecocq et al.
THERANOSTICS (2019)
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
Katrijn Broos et al.
THERANOSTICS (2018)
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
Zihai Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
Frederik Cleeren et al.
THERANOSTICS (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments
Anneleen Blykers et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Ruea-Yea Huang et al.
ONCOTARGET (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice
Alexis Broisat et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
M. Lemaire et al.
LEUKEMIA (2014)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)
S Andreae et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
